Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics
Retrieved on:
Wednesday, December 13, 2023
Genetics, Research, SAN, Therapy, Gene, Toxicity, IND, Biotechnology, FSHD, AVM, Patient, Mission, Idiopathic pulmonary fibrosis, Doctor of Philosophy, Altai, Drug resistance, TSE, Genome, Chromatin, Factorization of polynomials, Drug discovery, Cancer, TippingPoint, MBC, San Francisco Bay Area, Facioscapulohumeral muscular dystrophy, Pharmaceutical industry, Astellas Pharma
"We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.
Key Points:
- "We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.
- "It's such an honor to be a recipient of the Astellas Future Innovator Prize, which will further support TippingPoint's research," said Laura Hsieh, CEO of TippingPoint Biosciences.
- "Astellas' deep industry expertise coupled with MBC BioLabs' resources will play integral roles in accelerating our drug discovery development and successfully implementing TippingPoint's programs.
- Both TippingPoint Biosciences and Altay Therapeutics will reside at MBC BioLabs with the next year sponsored by Astellas.